Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.86 |
| ▸ | DRD3 | P35462 | 5/20 | 0.62 |
| ▸ | DRD4 | P21917 | 3/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354627 | 0.93 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL3320662 | 0.93 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL338733 | 0.93 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL15474018 | 0.93 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL339286 | 0.93 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL5146494 | 0.90 | DRD2 (0.74) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| SCHEMBL7543711 | 0.86 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| SCHEMBL8074280 | 0.86 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| SCHEMBL8074250 | 0.86 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| Hydrochloric Acid SCHEMBL7932989 | 0.85 | DRD2 (0.81) | DRD2DRD3DRD4GRIN2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| US-6391915-B2 | ANTIULCER AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020006956-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-17 | — | — | US | disclosed |
| EP-0976720-A1 | PROPANOLAMINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | DRD2 141/4885DRD3 175/4885DRD4 284/4885 |
| US-20020006956-A1 | Propanolamine derivatives | PNLIP, ADRB1, FABP2 | DRD2 115/4885DRD3 103/4885DRD4 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.